Zoledronic acid

Generic Name
Zoledronic acid
Brand Names
Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
Drug Type
Small Molecule
Chemical Formula
C5H10N2O7P2
CAS Number
118072-93-8
Unique Ingredient Identifier
70HZ18PH24
Background

Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...

Indication

Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...

Associated Conditions
Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
Associated Therapies
Bone Mineral Density
Clinical Trials
Related News

Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

First Posted Date
2006-08-17
Last Posted Date
2019-06-14
Lead Sponsor
Radiation Therapy Oncology Group
Target Recruit Count
261
Registration Number
NCT00365105
Locations
🇺🇸

Providence Cancer Center at Providence Hospital, Mobile, Alabama, United States

🇺🇸

Radiation Oncology Center - Roseville, Roseville, California, United States

🇺🇸

Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center, Pomona, California, United States

and more 144 locations

Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women

Not Applicable
Completed
Conditions
Osteoporosis
Interventions
Drug: zoledronic acid
First Posted Date
2006-08-08
Last Posted Date
2017-04-21
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
35
Registration Number
NCT00361595
Locations
🇺🇸

The Cleveland Clinic Foundation, Cleveland, Ohio, United States

Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss

First Posted Date
2006-07-17
Last Posted Date
2013-07-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
135
Registration Number
NCT00352846
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events

Phase 4
Completed
Conditions
Thalassemia
First Posted Date
2006-06-29
Last Posted Date
2012-05-01
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
60
Registration Number
NCT00346242
Locations
🇬🇷

Novartis Investigative Site, Athens, Greece

Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer

First Posted Date
2006-06-06
Last Posted Date
2017-02-07
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
411
Registration Number
NCT00334139
Locations
🇩🇪

Novartis Investigative Site, Ulm, Germany

Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

First Posted Date
2006-06-02
Last Posted Date
2011-11-16
Lead Sponsor
Novartis
Target Recruit Count
83
Registration Number
NCT00332709
Locations
🇩🇪

Novaertis Investigative Site, Hamein, Germany

🇩🇪

Novartis Investigative Site, Witten, Germany

A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

First Posted Date
2006-06-02
Last Posted Date
2014-11-25
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
11
Registration Number
NCT00333229
Locations
🇩🇪

Novartis Investigative Site, Marburg, Germany

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Phase 3
Completed
Conditions
Bone Metastases
Interventions
Biological: Denosumab
Drug: Zoledronic Acid
First Posted Date
2006-05-29
Last Posted Date
2022-11-07
Lead Sponsor
Amgen
Target Recruit Count
1779
Registration Number
NCT00330759

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

First Posted Date
2006-05-17
Last Posted Date
2013-03-13
Lead Sponsor
Wales Cancer Trials Unit
Target Recruit Count
1404
Registration Number
NCT00326820
Locations
🇬🇧

St. Mary's Hospital, Newport, England, United Kingdom

🇬🇧

Dorset Cancer Centre, Poole Dorset, England, United Kingdom

🇬🇧

Alexandra Healthcare NHS, Redditch, Worcestershire, England, United Kingdom

and more 76 locations

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

Phase 3
Completed
Conditions
Bone Metastases
Interventions
Drug: zoledronic acid
Biological: denosumab
First Posted Date
2006-05-04
Last Posted Date
2018-08-29
Lead Sponsor
Amgen
Target Recruit Count
1904
Registration Number
NCT00321620
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy